REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/22/2026
Back to search
Official data from USPTO
GD3 GENESIS DRUG DISCOVERY & DEVELOPMENT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
48
Latest update
06/23/2026
Trademark type
Combined
Nice classes
42
Filing date
10/26/2017
Registration date
06/22/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/22/2021
Last transaction
06/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2017-00-00
First use in commerce
2017-00-00
Drawing code
3
Owner type
16
Owner location
Hamilton, NJ, US
Examiner
HETZEL, DANNEAN
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "GD3 GENESIS DRUG DISCOVERY & DEVELOPMENT" and a design. The letters "G" and "D" are depicted inside a bisected oblong shape representing a pill. The letter "G" is in white with an outline in various shades of red. The letter "D" is in white with an outline in various shades of grey. The left half of the pill design with the letter "G" is in various shades of red. The right side of the pill design with the letter "D" is in various shades of grey. The number "3" is depicted in red with a white outline inside a stylized depiction of a molecule located to the upper right of the "GD" lettering. The molecule consists of four gold spheres representing atoms, which are connected by three straight bands in various shades of grey representing bonds. The stylized wording "GENESIS" appears in red below the "GD" lettering and pill design. The stylized wording "DRUG DISCOVERY & DEVELOPMENT" appears in smaller black font below the wording "GENESIS".
Holders and representatives
Holders
Genesis Drug Discovery & Development, LLC
Representatives
Christina E. Brule Heslin Rothenberg Farley & Mesiti P.C.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific study and research in the fields of medicinethe prevention and treatment of illnessdrug screeningmode of action of medicines in animal modelspharmacokinetic evaluation and preclinical evaluation of lead compounds in drug discovery
Publications
History of USPTO decisions and trademark events.
48 publications found
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/15/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/15/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/15/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/15/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/22/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/18/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/17/2021
DOCK
ASSIGNED TO EXAMINER
04/30/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/28/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/28/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/21/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/02/2020
GNRT
NON-FINAL ACTION E-MAILED
11/02/2020
CNRT
SU - NON-FINAL ACTION - WRITTEN
11/02/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/31/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/31/2020
IUAF
USE AMENDMENT FILED
10/16/2020
EISU
TEAS STATEMENT OF USE RECEIVED
10/16/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/12/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/17/2020
PUBO
PUBLISHED FOR OPPOSITION
03/17/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/03/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/14/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/14/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/01/2019
GNFR
FINAL REFUSAL E-MAILED
11/01/2019
CNFR
FINAL REFUSAL WRITTEN
11/01/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/10/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
03/28/2019
ALIE
ASSIGNED TO LIE
03/26/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
09/06/2018
GNSL
LETTER OF SUSPENSION E-MAILED
09/06/2018
CNSL
SUSPENSION LETTER WRITTEN
09/06/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/18/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/17/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/17/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/21/2018
GNRT
NON-FINAL ACTION E-MAILED
02/21/2018
CNRT
NON-FINAL ACTION WRITTEN
02/21/2018
DOCK
ASSIGNED TO EXAMINER
02/06/2018
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/04/2017
NWAP
NEW APPLICATION ENTERED
10/30/2017
Continuous trademark protection
Get notified about every new filing that threatens GD3 GENESIS DRUG DISCOVERY & DEVELOPMENT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.